January 17-19, 2018
Miami, Florida


HAI reserves the right to modify this preliminary program (including order of sessions/lectures).

The event will be held at the Miami Beach Resort.  

Wednesday, January 17, 2018
11:00 amCheck-in
11:45Welcome NotesKeith Johnson
Massachusetts General Hospital, Boston, MA, US
12:00 pmSESSION 1: Methods and analysisCHAIRS:
Bradley Christian, University of Wisconsin-Madison, Madison, WI, US
Sandra Sanabria, Genentech, South San Francisco, CA, US
12:00Serial measurements with Rousset-Style (GTM) PVC are less precise than with traditional approachesChristopher Schwarz, Mayo Clinic, Rochester, MN, US
12:15Modeling amyloid, tau, and cortical thickness changes across the Alzheimer's disease spectrumJungho Cha, University of California, San Francisco, CA, US
12:30Amyloid load - a more sensitive outcome measure for quantifying amyloid-betaRoger Gunn, Invicro, London, United Kingdom
12:45Data-driven Tau-PET covariance networks enhance associations with cognition in Alzheimer's disease.Jacob Vogel, Montreal Neurological Institute, Montreal, QC, Canada
1:00Regional tau elevation patterns in clinically normal adults using sparse k-means clustering
Kirsten Moody, Massachusetts General Hospital, Harvard Medical School, Boston, MA, US
1:15Evaluation of visual interpretation methods for Tau PET imaging
Ida Sonni, University of California, Berkeley, CA, US
1:30Discussion Session 1
2:00POSTER SESSION 1 and Coffee Break
3:30SESSION 2: New tracersCHAIRS:
Chester Mathis, University of Pittsburgh, Pittsburgh, PA, US
Roger Gunn, Invicro, London, UK
3:30PET imaging of synaptic density in Alzheimer's diseaseMing-Kai Chen, Yale University School of Medicine, New Haven, CT, US
3:45Characterizing the relationship of [18F]GTP1 (Genentech tau probe 1) PET imaging with Alzheimer's disease pathophysiologySandra Sanabria, Genentech, Inc., South San Francisco, CA, US
4:00A head-to-head comparison between [11C]PBB3 and [18F]PM-PBB3 in patients with AD and non-AD tauopathy
Manabu Kubota, National Institute of Radiological Sciences, Chiba, Japan
4:15Clinical evaluation of 18F-PI-2620, a next generation tau PET agent in subjects with Alzheimer's disease and Progressive Supranuclear PalsyAndrew Stephens, Piramal Imaging, Berlin, Germany
4:30Discussion Session 2
5:00SESSION 3: MK-6240Chairs:
Julie Price, ‎Massachusetts General Hospital, Boston, MA, US
Robert Koeppe, University of Michigan, Ann Arbor, MI, US
5:00Clinical validation of the novel PET tracer [18F]MK6240 for in vivo quantification of neurofibrillary tanglesPedro Rosa-Neto, McGill Uiversity, Montreal, QC, Canada
5:15Test-retest characterization and pharmacokinetic properties of [18F]MK-6240Cristian Salinas, Biogen, Cambridge, MA, US
5:30In vivo observations and quantification of tau with [F-18]MK-6240 PET from young controls to Alzheimer's diseaseTobey Betthauser, University of Wisconsin-Madison, Madison, WI, US
5:45Tau imaging in Alzheimer's disease with 18F-MK6240, a second generation selective tau tracerChristopher Rowe, Austin Health, Melbourne, Australia
6:00Discussion Session 3
6:30-8:30Welcome Reception
Thursday, January 18, 2018
7:30amCheck-in and Breakfast
8:30SESSION 4: Pathological correlatesCHAIRS:
Melissa Murray, Mayo Clinic, Jacksonville, FL, US
Milos Ikonomovic, University of Pittsburgh, Pittsburgh, PA, US
8:30Autoradiographic Evaluation of MK-6240 compared to AV-1451Val Lowe, Mayo Clinic, Rochester, MN, US
8:45In vivo and in vitro [18F]MK6240 show neurofibrillary tangles deposition heterogeneity in individuals with a wide range of cognitive symptoms
Tharick Pascoal, McGill University, Montreal, QC, Canada
9:00Multi-site study of PiB-PET imaging using the Centiloid method: relationships to pathological measures of beta-amyloid pathologyRenaud La Joie, University of California, San Francisco, CA, US
9:15[F-18]-AV-1451 binding profile in Chronic Traumatic Encephalopathy: a postmortem case seriesCinthya Aguero Murillo, Massachusetts General Hospital, Boston, MA, US
9:30Neuropathological and biochemical correlates of tau and amyloid PET imaging in two autopsy brainsMilos Ikonomovic, University of Pittsburgh, Pittsburgh, PA, US
9:45Discussion Session 4
10:15POSTER SESSION 2A and Coffee Break
11:00Keynote LectureWilliam Seeley, University of California, San Francisco, CA, US
11:30Keynote Discussion
11:45SESSION 5: Genetically determined ADCHAIRS:
Eric McDade, Washington University in Saint Louis, St. Louis, MO, US
Bill Klunk, University of Pittsburgh, Pittsburgh, PA, US
11:45Genetic and environmental factors are differentially related to ABeta burden in the presymptomatic phase of autosomal dominant and sporadic Alzheimer's diseaseJulie Gonneaud, McGill University, Montreal, QC, Canada
12:00 pmIn vivo measurements of cortical thickness, amyloid and tau pathology, and episodic memory in preclinical autosomal dominant Alzheimer's diseaseYakeel Quiroz, Massachusetts General Hospital, Harvard Medical School, Boston, MA, US
12:15Comparison of striatal longitudinal changes in amyloid deposition in non-demented elderly and Down syndromeDana Tudorascu, University of Pittsburgh, Pittsburgh, PA, US
12:30[F-18]AV-1451 PET in non-demented adults with Down Syndrome is related to both amyloid and ageAnn Cohen, University of Pittsburgh, Pittsburgh, PA, US
12:45Baseline amyloid PET and longitudinal change in non-amyloid biomarkers from the DIAN StudyEric McDade, Washington University in Saint Louis, St. Louis, MO, US
1:00Discussion Session 5
2:45SESSION 6: Amyloid and tau: correlations with patient characteristics and CSFCHAIRS:
Oskar Hansson, Lund University, Lund, Sweden
Agneta Nordberg, Karolinska Institute, Stockholm, Sweden
2:45Genotype-dependent longitudinal trajectories of brain metabolism and cognition in autosomal dominant AD
Elena Rodriguez-Vieitez, Karolinska Institute, Stockholm, Sweden
3:00Coupling between amyloid and tau occurs at a younger age in APOE E4 carriers than in non-carriers
Heidi Jacobs, Massachusetts General Hospital, Harvard Medical School, Boston, US
3:15Greater tau load and reduced cortical thickness in the parietal cortex of APOE ε4 negative AD patientsNiklas Mattsson, Lund University, Lund, Sweden
3:30Sex-specific effects on cognitive decline in preclinical Alzheimer's disease: findings from ADNI, AIBL and HABSRachel Buckley, Massachusetts General Hospital, Harvard Medical School, Boston, MA, US
3:45Distinct information from CSF Tau and AV1451 PET measures in nondemented individualsElizabeth Mormino, Stanford University, Stanford, CA, US
4:00Abnormal CSF ABeta changes do not reliably precede florbetapir-PET increases in ABeta-negative normals followed longitudinallySusan Landau, University of California, Berkeley, CA, US
4:15Discussion Session 6
4:45Tau Consortium Announcement
4:50POSTER SESSION 2B and Coffee Break
5:35 - 7:30Networking Reception
Friday, January 19, 2018
7:30amCheck-in and Breakfast
8:30SESSION 7: Staging and longitudinal studiesCHAIRS:
Keith Johnson, Massachusetts General Hospital, Boston, MA, US
Reisa SperlingBrigham and Women's Hospital, Boston, MA, US
8:30Longitudinal tau-PET in aging and Alzheimer's diseaseClifford Jack, Mayo Clinic, Rochester, MN, US
8:45Longitudinal [18F]-AV-1451 Tau-PET scans in healthy older adults and Alzheimer's diseaseTheresa Harrison, University of California, Berkeley, CA, US
9:00Where matters most: regional amyloid deposition predict progression from preclinical to prodromal stages of Alzheimer's diseaseGerard Bischof, University Hospital Cologne, Cologne, Germany
9:15In-vivo staging of regional amyloid deposition: evidence for validity and clinical significance from two independent cohort studiesMichel Grothe, German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany
9:30Predictors of regional AV1451 uptake in non-demented older adultsMurat Bilgel, National Institute on Aging, Baltimore, MD, US
9:45Discussion Session 7
10:15POSTER SESSION 3A and Coffee Break
11:00SESSION 8: Applications in Clinical PopulationsCHAIRS:
Gil Rabinovici, University of California, San Francisco,
Rik Ossenkoppele, VU University Medical Center, Amsterdam, Netherlands
11:00Impact of the appropriate use criteria: effect of amyloid imaging on diagnosis and patient management in an unselected memory clinic cohort: the ABIDE projectArno de Wilde, VU University Medical Center, Amsterdam, Netherlands
11:15The influence of age at onset on regional [18F]AV-1451 uptake in atypical Alzheimer's diseaseJennifer Whitwell, Mayo Clinic, Rochester, MN, US
11:30Hemispheric asymmetry on structural MRI, [18F]AV-1451-PET, and [11C]PIB-PET across clinical phenotypes of Alzheimer's diseaseAdrienne Visani, University of California, San Francisco, CA, US
11:45Detection of Tau pathology in Gerstmann-Sträussler-Scheinker Disease (PRNP F198S) by [18F]Flortaucipir PETShannon Risacher, Indiana University School of Medicine, Indianapolis, IN, US
12:00pmFDG-PET in tau-negative amnestic dementia resembles that of autopsy proven hippocampal sclerosisHugo Botha, Mayo Clinic, Rochester, MN, US
12:15Discussion Session 8
2:00Keynote LecturePeter Davies, Northwell Health, Great Neck, NY, US
2:30Keynote Discussion
2:45SESSION 9: Early Detection and PredictionCHAIRS:
Bill Jagust, University of California, Berkeley, CA, US
Beth Mormino, Standford University, Stanford, CA, US
2:45Early detection of longitudinal amyloid-related cognitive decline in middle-aged and initially amyloid-negative adultsMichelle Farrell, University of Texas at Dallas, Dallas, TX, US
3:00Prediction of incident sporadic Alzheimer dementia: longitudinal biomarkers and clinical changesBeau Ances, Washington University in Saint Louis, St. Louis, MO, US
Multiple brain markers contribute to risk of progression on the Clinical Dementia Rating Scale in clinically normal older adultsTaylor Neal, Massachusetts General Hospital, Boston, MA, US
3:30Low levels of brain beta-amyloid predict tau deposition and memory decline in agingStephanie Leal, University of California, Berkeley, CA, US
3:45Discussion Session 9
4:15POSTER SESSION 3B and Coffee Break
5:00SESSION 10: AD-vascular interactionsCHAIRS:
Tammie Benzinger, Washington University in Saint Louis, St. Louis, MO, US and Sylvia Villeneuve, McGill University, Montreal, QC, Canada
5:00Amyloid deposition, small-vessel disease accrual and neurodegeneration, and progression to Mild Cognitive Impairment (MCI) in cognitively normal older adultsNeelesh Nadkarni, University of Pittsburgh, Pittsburgh, PA, US
5:15The association of mid- and late-life systemic inflammation with brain amyloid deposition: atherosclerosis risk in communities-PET StudyKeenan Walker, Johns Hopkins University, Baltimore, MD, US
5:30Beta-amyloid burden and vascular risk interact to predict neocortical tau PET signal in clinically normal older individualsJennifer Rabin, Massachusetts General Hospital, Boston, MA, US
5:45Discussion Session 10
6:05Awards Ceremony
6:15Closing NotesKeith Johnson, Massachusetts General Hospital, Boston, MA, US

The 16th Mild Cognitive Impairment Symposium and Special Topic Workshop (CME/CE accredited) will follow immediately on January 20-21, 2018 at the same venue. 

You may review themes, the program and speakers at the MCI website.



Peter Davies received a BSc and a PhD, both in Biochemistry from the University of Leeds, England. He was a post-doctoral fellow in the Department of Pharmacology at the University of Edinburgh, Scotland, before joining the staff of the Medical Research Council Brain Metabolism Unit in Edinburgh in 1974, where he began his research on Alzheimer’s disease.

Dr. Davies’ early work was instrumental in the development of the currently approved drugs for Alzheimer’s disease — Aricept, Exelon and Razodyne. In 1977, he moved to Albert Einstein College of Medicine in the Bronx, NY, where he was a professor in the departments of pathology and neuroscience. Dr. Davies became the Scientific Director of the Litwin/Zucker Center for Research on Alzheimer’s Disease at Northwell Health’s Feinstein Institute for Medical Research in 2006.

For more than 35 years, Dr. Davies’ research has been focused on biochemistry of Alzheimer’s disease. He has published over 250 research papers and has been particularly interested in the development of new treatments and diagnostic tests for Alzheimer’s disease. He has received numerous awards for his research, including the City of New York Liberty Medal, a Lifetime Achievement Award from the International Congress on Alzheimer’s Disease (ICAD) and the first Metropolitan Life Foundation Prize. Dr Davies has also received two MERIT awards from the National Institutes of Health (NIMH, 1989-1999, and NIA 2003-2013).



Dr. Seeley attended medical school at the University of California at San Francisco (UCSF), where he first encountered patients with frontotemporal dementia (FTD) in 1999, during a research elective with Dr. Bruce Miller. He then completed a neurology residency at Harvard Medical School, training at the Massachusetts General and Brigham & Women’s Hospitals. Returning to UCSF for a behavioral neurology fellowship, with Dr. Miller, Dr. Seeley developed expertise in the differential diagnosis and treatment of patients with neurodegenerative disease. He is currently an Associate Professor of Neurology at the UCSF Memory and Aging Center, where he participates in patient evaluation and management.

Dr. Seeley’s research in his Selective Vulnerability Research Laboratory concerns regional vulnerability in dementia, that is, why particular dementias target specific neuronal populations. Dr. Seeley addresses this question through behavioral, functional imaging and neuropathology studies. The goal of his research is to determine what makes brain tissues susceptible or resistant to degeneration, with an eye toward ultimately translating these findings into novel treatment approaches.


Wednesday, January 11, 2017
11:30 amCheck-in
12:30pmWelcome NotesKeith Johnson
Massachusetts General Hospital
12:40SESSION 1
Quantifying Tau and Amyloid PET Signal
Chester Mathis
University of Pittsburgh
Bradley Christian
University of Wisconsin
12:40Evaluating different in vivo measures of tau pathology for use as biomarkersAnne Maass
University of California , Berkeley
12:55Tau Load: a novel method for quantifying subject-specific neuropathologic tau signal from Flortaucipir PET Michael Navitsky
Avid Radiopharmaceuticals
1:10Recovering signal from AV1451 in frontotemporal lobar degeneration with partial volume correctionAdam Martersteck
Northwestern University Feinberg School of Medicine
1:25Unbiased clustering using entorhinal and neocortical tau-PET uptake on [18F]AV-1451 maps onto age and clinical presentation in Alzheimer's diseaseJennifer Whitwell
Mayo Clinic
1:40Nonlinear alignment of multimodal empirical distributions for Level-2 Centiloid transformations
Michael Properzi
Massachusetts General Hospital, Harvard Medical School
2:25Keynote Lecture: Tau Prion Strains: Implications for Imaging Marc Diamond
University of Texas Southwestern
2:55Keynote Discussion
3:10POSTER SESSION 1 and Coffee Break
Novel Tau Tracers
Julie Price
Massachusetts General Hospital
Robert Koeppe
University of Michigan
4:40Effects of [18F]AV-1451 binding in cerebellar gray and extra-cortical areasSuzanne Baker
Lawrence Berkeley National Laboratory
4:55[18F]MK-6240, a novel neurofibrillary tangles PET tracer: Evaluation in healthy subjects and Alzheimer's Disease patientsCyrille Sur
Merck & Co., Inc.
5:10Current efforts to overcome drawbacks of [11C]PBB3 by developing new PBB3 derivatives: first-in-human PET study with [18F]AM-PBB3
Hitoshi Shimada
National Institute of Radiological Sciences
5:25Evaluation of baseline and longitudinal tau burden in Alzheimer’s disease using [18F]GTP1 (Genentech tau probe 1) PET imaging
Sandra Sanabria
Genentech Inc.
5:40Invited Lecture: Molecular Imaging Analysis for Tracer Validation and Clinical TrialsRoger Gunn
Imanova Ltd
6:30-8:30Welcome Reception
Thursday, January 12, 2017
7:00amCheck-in and Breakfast
Neuropathology I: Tau PET Ligand Selectivity and Comparative Studies
William Klunk
University of Pittsburgh
Milos Ikonomovic
University of Pittsburgh
8:00Evaluation of the selectivity of Tau PET radioligand THK5351 in AD brain in vitro and nonhuman primate brain in vivoQi Guo
AbbVie Inc.
8:15Characterizing the “off-target” binding of 18F-THK5351 in Alzheimer’s disease: correlation between ante-mortem and post-mortem findings
Ryuichi Harada
Tohoku University Graduate School of Medicine
8:30In vitro binding properties comparison of the tau PET tracers THK5117, THK5351, PBB3 and T807 in autopsy brain from Alzheimer diseases casesLaetitia Lemoine
Karolinska Institute
8:45An autoradiographic evaluation of THK-5351 compared to AV-1451Melissa Murray
Mayo Clinic
9:30POSTER SESSION 2A and Coffee Break
10:15SESSION 4
Neuropathology II: PET to Autopsy Correlations
Melissa Murray
Mayo Clinic
Teresa Gomez-Isla
Massachusetts General Hospital
10:15Neuropathology and biochemical correlations of [F-18]AV-1451 and [C-11]PiB PET imaging in a subject with Alzheimer's diseaseMilos Ikonomovic
University of Pittsburgh
10:30Neuroimaging-pathologic correlation of [F-18]-AV-1451 in an autopsy confirmed Parkinson's disease caseMarta Marquie-Sayagues
MassGeneral Institute for Neurodegenerative Disease
10:45Multimodal evaluation of 18F-AV-1451 PET in an autopsy-confirmed corticobasal degeneration patientCorey McMillan
Perelman School of Medicine at the University of Pennsylvania
11:25Announcement: Alpha–synuclein Imaging PrizeJamie Eberling
The Michael J. Fox Foundation for Parkinson’s Research
11:30Keynote Lecture: Tau PET for Alzheimer’s Disease: Possible Promise and Pitfalls
Thomas Beach
Banner Sunhealth Research Institute
12:00pmKeynote Discussion
Tau PET: Non-AD Targets
Gil Rabinovici
University of California, San Francisco
Brad Dickerson
Massachusetts General Hospital
1:4518F Flortaucipir binding in choroid plexus: association with race and hippocampus bindingChristopher Lee
Massachusetts General Hospital, Harvard Medical School
2:00[18F]Flortaucipir, aka [18F]AV-1451, Autoradiography Matches Immunofluorescent Staining From AT8 Tau Antibody in Chronic Traumatic Encephalopathy (CTE) Post-Mortem Brain Tissue Sections
Yin-Guo Lin
Avid Radiopharmaceuticals, Inc.
2:15Microscopic neuropathological evaluation of the binding profile of tau selective PET ligands in Alzheimer's disease and primary tauopathiesMelissa Wren
University College London
2:30AV-1451 tau-PET uptake in MAPT mutation carriers varies by tau isoformsDavid Jones
Mayo Clinic
2:4518F-AV-1451 binding in familial frontotemporal lobar degeneration with tau pathologyWilliam Kreisl
Columbia University
3:30POSTER SESSION 2B and Coffee Break
Thresholds and Centiloids
Keith Johnson
Massachusetts General Hospital
Susan Landau
University of California, Berkeley
4:15Defining cut-points for imaging biomarkers used in brain aging and Alzheimer's disease researchClifford Jack
Mayo Clinic
4:30Further adventures in the world of centiloidsRobert Koeppe
University of Michigan
6:30 - 8:30Networking Reception
Friday, January 13, 2017
7:00amCheck-in and Breakfast
Amyloid and Tau PET in Clinical Trials
Bill Jagust
University of California, Berkeley
Susan Resnick
National Institutes of Health
8:00The A4 Study: Preliminary Analyses of Baseline Tau PET Imaging Reisa Sperling
Harvard Medical School
8:15Conversion of aMCI subjects to AD in relation to [18F]flutemetamol Amyloid status, and hippocampal volume in a phase III longitudinal studyDavid Wolk
Perelman School of Medicine at the University of Pennsylvania
8:30Baseline 18F Flortaucipir SUVR, but not amyloid or cognition, predicts cognitive decline over 18 months in Phase 2 trial subjectsMichael Devous, Sr.
Avid Radiopharmaceuticals
8:45PET amyloid and tau imaging in a Phase 3 study of solanezumabMark Mintun
Avid Radiopharmaceuticals
9:30POSTER SESSION 3A and Coffee Break
10:15SESSION 8
Preclinical AD
Reisa Sperling
Harvard Medical School
Elizabeth Mormino
Stanford University
10:15Implementing and testing the new A/T/N classification in AIBL participants combining fluid (CSF) and different Aβ and tau imaging radiotracersVictor Villemagne
University of Melbourne
10:30The Relationship of Elevated Medial Temporal Lobe and Diffuse Brain Tau-PET Signal in Clinically Normal ParticipantsVal Lowe
Mayo Clinic
Prevalence and incidence of amyloid positivity in cognitively normal elderly individualsNeelesh Nadkarni
University of Pittsburgh
11:00Longitudinal tau accumulation is associated with cognitive decline in normal elderlyBernard Hanseeuw
Harvard Medical School
11:15Baseline amyloid burden predicts cognitive decline four years later in healthy adults: The value of a dose-response analysisMichelle Farrell
University of Texas at Dallas
12:00pmKeynote Lecture: Alzheimer’s disease clinical trials: 2017 updateHoward Feldman
University of California, San Diego
12:30Keynote Discussion
Amyloid, Tau, and Neurodegeneration
Clifford Jack
Mayo Clinic
Tammie Benzinger
Washington University at St Louis
2:15Neocortical Tau and hippocampus volume reflect distinct processes in preclinical Alzheimer's diseaseElizabeth Mormino
Stanford University
2:30Do neurodegeneration or amyloid pathology contribute to the relationship between AV-1451 and cognitive symptoms in Alzheimer's disease?Alexandre Bejanin
University of California, San Francisco
2:45Comparing the contributions of tau and neurodegenerative biomarkers to cognitive declineSusan Landau
University of California, Berkeley
3:00Differential genotypic variance in PET and CSF measures of amyloid burden: Findings from the DIAN StudyJasmeer Chhatwal
Massachusetts General Hospital
3:15Relationships between AV1451-PET and CSF biomarkers in a heterogeneous clinical sampleRenaud La Joie, University of California, San Francisco
4:00POSTER SESSION 3B and Coffee Break
4:45Awards Ceremony
4:50SESSION 10
Amyloid and Tau PET in Distinct Populations
Trey Hedden
Massachusetts General Hospital
Charles de Carli
University of California, Davis
4:50Association of regional FDG hypometabolism with age, amyloid, tau, and cardiac and metabolic conditions along the AD continuumPrashanthi Vemuri, Mayo Clinic
5:0518F-AV1451 PET in patients with subcortical vascular cognitive impairmentSang Won Seo, Sungkyunkwan University School of
5:20White matter hyperintensities and brain amyloid deposition: The ARIC-PET StudyRebecca Gottesman
Johns Hopkins University
5:35Association of amyloid-beta plaque accumulation and glucose hypometabolism in Down syndrome demonstrates pattern associated with Alzheimer's diseasePatrick Lao, University of Wisconsin
6:20Closing NotesKeith Johnson, Massachusetts General Hospital